Is olanzapine 10 mg (orange round tablet marked “ZP 10”) indicated for the treatment of chemotherapy‑induced nausea and vomiting?

Yes, olanzapine 10 mg is indicated for chemotherapy-induced nausea and vomiting

Olanzapine is recommended by the National Comprehensive Cancer Network (NCCN) as a first-line option for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, and it is also effective for breakthrough CINV despite being used "off-label" for this indication. 1, 2

Guideline-Based Indications

Highly Emetogenic Chemotherapy (HEC)

• The NCCN and American Society of Clinical Oncology (ASCO) recommend a 4-drug regimen including olanzapine 10 mg, an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone as first-line prophylaxis for highly emetogenic chemotherapy (Category 1 recommendation, high-quality evidence). 1, 2
• Olanzapine is given at 10 mg orally at bedtime on days 1-4 of the chemotherapy cycle. 2, 3
• This regimen applies to cisplatin-based chemotherapy and anthracycline-cyclophosphamide (AC) regimens commonly used in breast cancer. 2

Breakthrough CINV

• For patients who develop nausea or vomiting despite guideline-directed prophylaxis, olanzapine 5-10 mg daily is recommended as rescue therapy (Category 1). 1, 2
• In a phase III trial of 108 patients with breakthrough CINV, olanzapine was superior to metoclopramide: 70% vs 31% remained vomit-free (p<0.01) and 68% vs 23% remained nausea-free (p<0.01), with no grade 3-4 adverse events. 4, 2

Mechanism of Action

Olanzapine's antiemetic efficacy stems from its ability to antagonize multiple receptors involved in CINV pathways, including dopaminergic, serotonergic (5-HT2A/2C), adrenergic, histaminergic (H1), and muscarinic receptors. 1, 2 This broad receptor blockade addresses nausea pathways that 5-HT3 antagonists (like ondansetron) and NK1 antagonists alone cannot adequately suppress, particularly those mediated by dopamine and histamine. 2

Clinical Efficacy Evidence

Phase III Trial Data

• In patients receiving highly emetogenic chemotherapy, adding olanzapine to standard antiemetic prophylaxis achieved an 86% complete response rate (no vomiting, no rescue medication) versus 65% without olanzapine. 2
• The "no nausea" rate was 74% with olanzapine versus 45% without it, demonstrating particular efficacy for nausea control—a symptom often more difficult to prevent than vomiting. 2
• For delayed-phase CINV (24-120 hours post-chemotherapy), olanzapine 5 mg combined with standard therapy achieved a 79% complete response rate versus 66% with placebo (p<0.0001). 5

Important Safety Considerations

Common Side Effects

• Somnolence is the most common side effect, occurring in 35-44% of patients, which can be beneficial when dosed at bedtime but requires counseling about driving and operating machinery. 2, 6
• Other common effects include postural hypotension, constipation, dizziness, fatigue, and dyspepsia. 2

Critical Warnings

• Use with extreme caution in elderly patients due to FDA black box warning regarding increased mortality in elderly patients with dementia-related psychosis. 1, 2
• Consider a reduced dose of 5 mg in elderly or over-sedated patients to minimize sedation risk. 1
• Avoid concurrent use with benzodiazepines in elderly patients, as combined oversedation has been linked to fatal respiratory depression. 6
• Rare but serious skin reactions (DRESS syndrome) have been reported. 2

Drug Interactions

• Olanzapine does not inhibit or induce CYP3A4, avoiding the need for dexamethasone dose adjustments (unlike aprepitant, which requires dexamethasone dose reduction). 2
• Both olanzapine and ondansetron can contribute to sedation; patients should be counseled accordingly. 2

Clinical Algorithm for Use

Day 1 of Highly Emetogenic Chemotherapy

• NK1 receptor antagonist (aprepitant 125 mg PO or fosaprepitant 150 mg IV) 2
• 5-HT3 receptor antagonist (ondansetron 8 mg IV or granisetron 1 mg IV) 2
• Dexamethasone 20 mg IV (for AC regimens: day 1 only) 2
• Olanzapine 10 mg PO at bedtime 2

Days 2-4

• Continue olanzapine 10 mg PO at bedtime 2
• For cisplatin-based regimens, continue dexamethasone; for AC regimens, dexamethasone is omitted on days 2-4. 2

If Breakthrough CINV Occurs

• If olanzapine was not given prophylactically, add olanzapine 5-10 mg daily. 2, 4
• If olanzapine has already been used, consider switching to a drug from another class (additional NK1 antagonist, benzodiazepine, or cannabinoid). 2

Common Pitfalls to Avoid

• Do not use olanzapine for radiation-induced nausea and vomiting—ASCO guidelines do not recommend it for this indication; use 5-HT3 antagonist plus dexamethasone instead. 2
• Antiemetic effects are expected within the first 24 hours, not immediately, so counsel patients about the timeline. 3
• This is an off-label use—while strongly supported by guidelines and high-quality evidence, olanzapine is not FDA-approved specifically for CINV. 1, 2, 7